$99.1m out of $135m corresponds prorated 268 days (puts the SNY AG launch on or around 10/5/2011)
Note that this put the SNY launch of the AG before MNTA even obtained the TRO on 10/7/2011. So it is pretty clear that the launch of AG by SNY occured as rapidly as possible after the 9/19 approval of amphastar's product, as it would make sense to try to beat them to the market. And, SNY's actions reflect them taking no opinion about the outcome of the MNTA-Amphstar legal wrangling
Any comments here may have previously been disseminated on Twitter @BioDueDiligence or at www.biotechduediligence.com